Neogen (NASDAQ:NEOG – Get Free Report) announced its quarterly earnings results on Tuesday. The company reported $0.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.02), Yahoo Finance reports. The firm had revenue of $236.80 million for the quarter, compared to analysts’ expectations of $225.83 million. Neogen had a return on equity of 3.35% and a net margin of 0.17%. The business’s quarterly revenue was down 2.1% on a year-over-year basis. During the same period last year, the company posted $0.14 earnings per share. Neogen updated its FY 2025 guidance to EPS.
Neogen Stock Down 3.1 %
Shares of Neogen stock traded down $0.55 during trading on Wednesday, hitting $17.03. 2,552,199 shares of the stock traded hands, compared to its average volume of 2,116,519. The company has a fifty day moving average price of $15.80 and a two-hundred day moving average price of $15.25. Neogen has a twelve month low of $11.46 and a twelve month high of $24.09. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.66 and a current ratio of 3.82. The stock has a market cap of $3.69 billion, a P/E ratio of 1,704.70 and a beta of 1.20.
Analysts Set New Price Targets
A number of research analysts recently weighed in on the stock. StockNews.com upgraded shares of Neogen to a “sell” rating in a report on Wednesday, July 10th. Piper Sandler dropped their price objective on shares of Neogen from $19.00 to $17.00 and set a “neutral” rating on the stock in a research note on Monday, April 15th.
Neogen Company Profile
Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.
Recommended Stories
- Five stocks we like better than Neogen
- 3 Tickers Leading a Meme Stock Revival
- Joby Aviation Stock: The Case for Upside Just Got Stronger
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Conviction Firms for Microsoft’s Double-Digit Stock Upside
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- 5 Aggressive Growth Stocks for Long-Term Investors
Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.